Louvain-la-Neuve, Belgium, 19 November 2020 – IBA (Ion Beam Purposes S.A., EURONEXT), the world’s main supplier of proton remedy options for the remedy of most cancers, right now publicizes its enterprise replace for the third quarter ending 30 September 2020.
Olivier Legrain, Chief Government Officer of IBA SA, commented: “While the worldwide working setting continues to be impacted by the COVID-19 disaster, IBA’s enterprise is demonstrating encouraging resilience and is nicely positioned to climate ongoing disruption brought on by the pandemic. This resilience is especially evident within the strengthening of recurring revenues from sturdy performances of Dosimetry and Companies. Different Accelerators additionally continues to carry out very nicely and as IBA continues to display its market superiority, we’re seeing market share features in these companies as nicely.”
“As we glance to the approaching months and 2021, we’re happy to notice our sturdy internet money place, which has continued to enhance all year long. Because it stands, the tools backlog inside our Proton Remedy and Different Accelerators divisions stays at a file excessive and throughout the enterprise we’re making our greatest efforts to make sure installations proceed wherever doable, amidst journey restrictions and buyer constraints. The PT market stays energetic, with China persevering with to be a key strategic goal for proton remedy and we have been delighted to safe a licensing deal this quarter with CGNNT in China value at the least EUR 100 million.”
Throughout all enterprise traces, IBA’s focus stays on its core drivers of development: Know-how, Execution and Innovation.
- IBA’s unrivalled experience in particle acceleration spans 34 years and inside proton remedy, IBA has a longtime place as the biggest and most educated neighborhood with 59 facilities bought internationally and 36 treating sufferers each day.
- In September, IBA introduced that 100,000 sufferers have now been handled with IBA proton remedy methods all over the world, a key milestone for the Group and for sufferers.
- Throughout its vary of particle accelerators, IBA continues to ship progressive merchandise to satisfy new market wants, such because the manufacturing of radiopharmaceuticals which might be very important to be used in extreme illness prognosis and remedy or to sterilize medical units or different supplies as a greener various to current strategies corresponding to gamma sterilization.
- IBA strives to proceed offering probably the most technologically superior providing, which might be a key driver of the long run success of the enterprise.
- Enterprise operations have remained strong into the third quarter, albeit with ongoing delays within the set up of methods on account of the COVID-19 pandemic.
- Constructive enterprise supply is underpinned by a resilient monetary footing. Money management measures, in addition to quantities obtained from a licensing deal resulted in an (unaudited) gross money determine of EUR 122 million and internet money of EUR 33 million on the finish of September.
- IBA’s Gear and Companies backlog stays at an all-time excessive. The Firm stays dedicated to driving order consumption throughout all enterprise traces, underpinned by a give attention to innovation.
- Companies continued to carry out nicely, reflecting the truth that all proton remedy facilities have remained operational through the disaster. With Companies changing into an growing income driver, IBA has continued to put money into its service enterprise, whereas guaranteeing the best and streamlined method to this necessary income stream.
- China’s central Ministry of Well being has opened the appliance course of for the proton remedy licences that might be awarded in 2020. Purposes must be made by 31 December 2020 and outcomes are anticipated in early 2021.
- As introduced beforehand, IBA secured a licensing deal for the proton remedy answer Proteus®PLUS* with CGNNT in China value a minimal of EUR 100 million, with the primary cost of EUR 20 million obtained within the third quarter and an irrevocable letter of credit score issued by CGNNT for the remaining EUR 80 million. IBA will begin to acknowledge revenues from this deal in 2020.
- IBA is ideally positioned to seize alternatives in China, a market of key strategic significance. The Firm stays the proton remedy market chief within the area as demonstrated by the just lately introduced deal in Sichuan and settlement with CGNNT. This settlement gives IBA with a wider platform to satisfy the demand for multi-room configurations which might be anticipated within the coming years.
- In October, IBA obtained the NOC (No Objection Certificates) that enables the corporate to import its Proteus®ONE* answer into India.
- Despite the pandemic, IBA is actively engaged in discussions for additional worldwide tenders. IBA signed a contract in September with Sichuan Most cancers Hospital & Institute to put in a four-room Proteus®PLUS proton remedy system in Chengdu, Sichuan province, China.
- Different Accelerators continues to carry out nicely, with 14 methods bought this 12 months. There was growing demand for brand spanking new diagnostic radioisotopes which has helped the sturdy efficiency of RadioPharma Options.
- The Institute of Radioelements (IRE) in Belgium has additionally commissioned RadioPharma Options to put in a excessive power particle accelerator for the manufacturing of radioisotopes for the prognosis of quite a few most cancers sorts corresponding to neuroendocrine tumors and prostate most cancers.
- Industrial Options just lately signed a contract for the primary end-to-end Rhodotron® DUO answer for multi-purpose irradiation in Taiwan, value round EUR 8 million. The contract was signed with Shin-Ho Devices Co., LTD., a fully-owned subsidiary of CHC Healthcare Group in Taiwan.
- IBA Dosimetry order consumption stays sturdy because the enterprise unit continues to realize market share in high quality assurance for standard radiotherapy, whereas additionally confirming its management in dosimetry for proton remedy.
- A key precedence for the Group stays its focused funding in progressive proton remedy applied sciences in shut collaboration with our prospects and thru R&D partnerships to drive future development together with Movement Administration, Arc Remedy and FLASH Remedy.
- Inside Companies, funding has centered on guaranteeing extra streamlined companies and optimized upgrades, with the division changing into an more and more necessary driver of income.
- As well as, shut collaborations with Philips, Elekta and RaySearch Laboratories allow the most recent radiation remedy insights to be built-in into IBA’s current methods.
- On the Industrial Options aspect, the event of the Rhodotron® TT300 HE is progressing nicely. Utilizing high-energy electrons with this Rhodotron®, IBA’s buyer Northstar will be capable to keep away from the usage of uranium and supply an optimized methodology to ship technetium-99 that’s broadly used for medical diagnostics.
- IBA Dosimetry has been boosted by new progressive merchandise with myQA iON, the distinctive IBA Dosimetry Affected person QA software program answer for proton remedy, being permitted by the FDA in July.
All year long, IBA has remained dedicated to stringent money preservation measures. Because of this, the steadiness sheet stays sturdy, with an unaudited gross money place of EUR 122 million. These measures will proceed to mitigate uncertainty associated to the pandemic.
With the dearth of readability on future projections brought on by COVID-19, IBA believes its choice to withdraw steering for the short-term was prudent. The corporate intends to offer extra detailed steering as quickly as practicably doable. As acknowledged above, the Group will begin to recognise income from the CGNNT proton remedy deal in its 2020 full 12 months outcomes.
The principle space of focus for the Group continues to be on strategic R&D investments whereas driving effectivity throughout the enterprise.
Full 12 months 2020 outcomes: 25 March 2021
IBA (Ion Beam Purposes S.A.) is a world medical know-how firm centered on bringing built-in and progressive options for the prognosis and remedy of most cancers. The corporate is the worldwide know-how chief within the area of proton remedy, thought of to be probably the most superior type of radiation remedy obtainable right now. IBA’s proton remedy options are versatile and adaptable, permitting prospects to select from common full-scale proton remedy facilities in addition to compact, single room options. As well as, IBA additionally has a radiation dosimetry enterprise and develops particle accelerators for the medical world and business. Headquartered in Belgium and using about 1,500 individuals worldwide, IBA has put in methods the world over.
IBA is listed on the pan-European inventory trade NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). Extra info might be discovered at: www.iba-worldwide.com
*Proteus®ONE and Proteus®PLUS are model names of Proteus 235
For additional info, please contact:
Chief Monetary Officer
+32 10 475 890
Head of Company Communication
+32 10 475 890
For media and investor enquiries:
Consilium Strategic Communications
Amber Fennell, Angela Grey, Lucy Featherstone, Lizzie Seeley
+44 (0) 20 3709 5700